Evaluation of the new guideline for diagnosis and treatment catheter-related thrombosis in neonates on the neonatal intensive care unit

Composite efficacy endpoint consists of incidence of recurrent VTE and death as result of VTE, after start of anticoagulant therapy + 3 days.
Primary safety endpoint is the frequency of major bleeding during anticoagulation treatment.

Secondary efficacy endpoints consists of the individual components of the primary efficacy endpoint.
Secondary safety endpoints are the frequency of clinically relevant non-major bleeding and minor bleeding occurring during anticoagulation treatment.



Additional endpoints are the frequency of risk factors for thrombosis, the frequency of protocol violations and the frequency of long-term consequences of thrombosis, i.e. post thrombotic syndrome and the presence of residual thrombosis.